LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors!
This week’s newsletter is a bit lighter than usual, partly because it’s becoming increasingly difficult to find detailed information on new clinical trials. The trials are there, but the mechanisms behind the proposed drugs are often hard to identify. But I also wanted to make space for an important initiative.

​The Estradiol Initiative is calling on all of us to help apply pressure to make estradiol-based ADT therapy a standard of care. In addition to being significantly less expensive, this approach may also offer fewer side effects.

We have already seen how coordinated advocacy can influence outcomes. Capivasertib, for the treatment of prostate cancer, was approved by FDA with a 7–1 vote, in large part due to the lobbying efforts of Gina B. Carithers, CEO of the Prostate Cancer Foundation.

It is time to make our voices heard. For this reason, I have created a dedicated page on the website where you can send an email urging Gina B. Carithers to support the approval of this therapy. You will find more information and can send your message directly from this page: https://prostatewarriors.com/te2-initiative/​
​
Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.

Clinical Research

• Phase 1b Trial: AKY-2519 Targeting B7-H3 in mCRPC
  ​A Phase 1b clinical trial has launched to evaluate AKY-2519, a miniprotein radioconjugate targeting B7-H3 (CD276) in patients with metastatic castration-resistant prostate cancer (mCRPC). This open-label study is enrolling both Pluvicto-naïve and Pluvicto-experienced patients, using an alpha-emitting actinium-225 payload to deliver potent cell-killing radiation directly to tumors. Because B7-H3 is often overexpressed in metastatic lesions regardless of PSMA levels, this therapy is positioned as a critical option for patients who are PSMA-low or resistant to current radioligand therapies. Preliminary safety and efficacy data from the trial are expected in 2027.
  ​

Preclinical Research & Reviews

• STEAP1-Targeted Immune-Engaging ADC Platform
  ​Researchers have developed a new antibody-drug conjugate (ADC) platform using vandortuzumab to target STEAP1, an antigen highly overexpressed in castration-resistant prostate cancer. This platform is unique because it is designed as an immune-engaging agent rather than a simple cytotoxic delivery system; it utilizes STEAP1-specific Fcγ receptor engagement to prime an adaptive immune response. Preclinical studies using exatecan-based payloads demonstrated durable tumor control and induced immune memory in animal models, suggesting this approach can convert immune-silent environments into those capable of sustained T-cell surveillance.
  ​​
  ​
• CRISPR RNA-Guided Precision Kill-Switch
  ​A novel CRISPR system utilizing the Cas12a2 enzyme has been developed as a precision “kill-switch” that eliminates cancer cells by sensing their specific RNA signatures. Unlike traditional CRISPR that edits DNA, Cas12a2 activates only when its guide RNA perfectly matches a target, such as a mutant transcript, at which point it destroys the cell’s genome to trigger death. This preclinical strategy has shown a 50% reduction in tumor volume in mouse models and offers a flexible platform that can be reprogrammed to target various driver mutations or fusion transcripts across many different cancer types.
  ​​
  ​
• Proteogenomic Mapping for Cancer Drug Repurposing
  ​A large-scale international study of over 78,000 people has produced a comprehensive map of how genetic variants control the levels of proteins in human blood. This “proteogenomic” framework provides a crucial bridge between DNA and clinical disease, allowing researchers to identify proteins that are on a causal path to cancer and validate them as drug targets. By linking genetic risk to specific protein patterns, this molecular “diseasome” map enables the repurposing of existing drugs,such as using the TYK2 inhibitor, to treat new indications where the drug’s action aligns with protective genetic patterns.
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max